Participants With Drug-Related Adverse Events
Weeks 0 to 12
All Participants as Treated

	f						m						Total					
	Placebo		Low Dose		High Dose		Placebo		Low Dose		High Dose		Placebo		Low Dose		High Dose	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Participants in population	53		50		40		33		34		44		86		84		84	
with one or more drug-related adverse events	28	(52.8)	41	(82.0)	32	(80.0)	16	(48.5)	32	(94.1)	38	(86.4)	44	(51.2)	73	(86.9)	70	(83.3)
with no drug-related adverse events	25	(47.2)	9	(18.0)	8	(20.0)	17	(51.5)	2	(5.9)	6	(13.6)	42	(48.8)	11	(13.1)	14	(16.7)
Cardiac disorders	**4**	**(7.5)**	**4**	**(8.0)**	**4**	**(10.0)**	**2**	**(6.1)**	**3**	**(8.8)**	**0**	**(0.0)**	**6**	**(7.0)**	**7**	**(8.3)**	**4**	**(4.8)**
Atrial fibrillation	1	(1.9)	0	(0.0)	2	(5.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)	2	(2.4)
Atrial flutter	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(2.9)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)
Atrioventricular block first degree	1	(1.9)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)	0	(0.0)
Atrioventricular block second degree	0	(0.0)	0	(0.0)	0	(0.0)	1	(3.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)	0	(0.0)

Participants With Drug-Related Adverse Events
Weeks 0 to 12
All Participants as Treated

	f						m						Total					
	Placebo		Low Dose		High Dose		Placebo		Low Dose		High Dose		Placebo		Low Dose		High Dose	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Bradycardia	1	(1.9)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)	0	(0.0)
Bundle branch block right	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(2.9)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)
Cardiac failure congestive	1	(1.9)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)	0	(0.0)
Myocardial infarction	2	(3.8)	1	(2.0)	1	(2.5)	0	(0.0)	0	(0.0)	0	(0.0)	2	(2.3)	1	(1.2)	1	(1.2)
Palpitations	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(2.9)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)
Sinus arrhythmia	0	(0.0)	0	(0.0)	0	(0.0)	1	(3.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)	0	(0.0)
Sinus bradycardia	2	(3.8)	1	(2.0)	0	(0.0)	0	(0.0)	1	(2.9)	0	(0.0)	2	(2.3)	2	(2.4)	0	(0.0)
Supraventricular extrasystoles	0	(0.0)	1	(2.0)	1	(2.5)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	1	(1.2)
Ventricular extrasystoles	0	(0.0)	1	(2.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)
Wolff-parkinson-white syndrome	0	(0.0)	1	(2.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)

Participants With Drug-Related Adverse Events
Weeks 0 to 12
All Participants as Treated

	f						m						Total					
	Placebo		Low Dose		High Dose		Placebo		Low Dose		High Dose		Placebo		Low Dose		High Dose	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Congenital, familial and genetic disorders	**0**	**(0.0)**	**0**	**(0.0)**	**0**	**(0.0)**	**0**	**(0.0)**	**1**	**(2.9)**	**0**	**(0.0)**	**0**	**(0.0)**	**1**	**(1.2)**	**0**	**(0.0)**
Ventricular septal defect	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(2.9)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)
Ear and labyrinth disorders	**0**	**(0.0)**	**2**	**(4.0)**	**1**	**(2.5)**	**0**	**(0.0)**	**0**	**(0.0)**	**0**	**(0.0)**	**0**	**(0.0)**	**2**	**(2.4)**	**1**	**(1.2)**
Tinnitus	0	(0.0)	1	(2.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)
Vertigo	0	(0.0)	1	(2.0)	1	(2.5)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	1	(1.2)
Eye disorders	**0**	**(0.0)**	**0**	**(0.0)**	**1**	**(2.5)**	**0**	**(0.0)**	**1**	**(2.9)**	**0**	**(0.0)**	**0**	**(0.0)**	**1**	**(1.2)**	**1**	**(1.2)**
Vision blurred	0	(0.0)	0	(0.0)	1	(2.5)	0	(0.0)	1	(2.9)	0	(0.0)	0	(0.0)	1	(1.2)	1	(1.2)
Gastrointestinal disorders	**1**	**(1.9)**	**6**	**(12.0)**	**3**	**(7.5)**	**3**	**(9.1)**	**2**	**(5.9)**	**7**	**(15.9)**	**4**	**(4.7)**	**8**	**(9.5)**	**10**	**(11.9)**
Abdominal pain	0	(0.0)	1	(2.0)	1	(2.5)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	1	(1.2)
Diarrhoea	0	(0.0)	3	(6.0)	0	(0.0)	3	(9.1)	0	(0.0)	2	(4.5)	3	(3.5)	3	(3.6)	2	(2.4)
Dyspepsia	1	(1.9)	0	(0.0)	0	(0.0)	0	(0.0)	1	(2.9)	0	(0.0)	1	(1.2)	1	(1.2)	0	(0.0)
Gastrooesophageal reflux disease	1	(1.9)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)	0	(0.0)

Nausea	0	(0.0)	2	(4.0)	2	(5.0)	0	(0.0)	1	(2.9)	1	(2.3)	0	(0.0)	3	(3.6)	3	(3.6)

Participants With Drug-Related Adverse Events
Weeks 0 to 12
All Participants as Treated

	f						m						Total					
	Placebo		Low Dose		High Dose		Placebo		Low Dose		High Dose		Placebo		Low Dose		High Dose	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Salivary hypersecretion	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	3	(6.8)	0	(0.0)	0	(0.0)	3	(3.6)
Stomach discomfort	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(2.3)	0	(0.0)	0	(0.0)	1	(1.2)
Vomiting	0	(0.0)	2	(4.0)	0	(0.0)	0	(0.0)	0	(0.0)	3	(6.8)	0	(0.0)	2	(2.4)	3	(3.6)
General disorders and administration site conditions	**11**	**(20.8)**	**23**	**(46.0)**	**17**	**(42.5)**	**7**	**(21.2)**	**20**	**(58.8)**	**18**	**(40.9)**	**18**	**(20.9)**	**43**	**(51.2)**	**35**	**(41.7)**
Application site bleeding	0	(0.0)	1	(2.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)
Application site dermatitis	2	(3.8)	5	(10.0)	4	(10.0)	3	(9.1)	4	(11.8)	3	(6.8)	5	(5.8)	9	(10.7)	7	(8.3)
Application site desquamation	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(2.9)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)
Application site discharge	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(2.3)	0	(0.0)	0	(0.0)	1	(1.2)
Application site discolouration	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(2.9)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)

Participants With Drug-Related Adverse Events
Weeks 0 to 12
All Participants as Treated

	f						m						Total					
	Placebo		Low Dose		High Dose		Placebo		Low Dose		High Dose		Placebo		Low Dose		High Dose	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Application site erythema	2	(3.8)	5	(10.0)	5	(12.5)	1	(3.0)	7	(20.6)	10	(22.7)	3	(3.5)	12	(14.3)	15	(17.9)
Application site induration	0	(0.0)	0	(0.0)	0	(0.0)	1	(3.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)	0	(0.0)
Application site irritation	3	(5.7)	6	(12.0)	5	(12.5)	0	(0.0)	3	(8.8)	4	(9.1)	3	(3.5)	9	(10.7)	9	(10.7)
Application site pain	0	(0.0)	0	(0.0)	2	(5.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	2	(2.4)
Application site perspiration	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	2	(4.5)	0	(0.0)	0	(0.0)	2	(2.4)
Application site pruritus	4	(7.5)	12	(24.0)	10	(25.0)	2	(6.1)	10	(29.4)	12	(27.3)	6	(7.0)	22	(26.2)	22	(26.2)
Application site reaction	0	(0.0)	0	(0.0)	1	(2.5)	1	(3.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)	1	(1.2)
Application site swelling	0	(0.0)	0	(0.0)	1	(2.5)	0	(0.0)	1	(2.9)	1	(2.3)	0	(0.0)	1	(1.2)	2	(2.4)
Application site urticaria	0	(0.0)	0	(0.0)	1	(2.5)	0	(0.0)	2	(5.9)	0	(0.0)	0	(0.0)	2	(2.4)	1	(1.2)

Participants With Drug-Related Adverse Events
Weeks 0 to 12
All Participants as Treated

	f						m						Total					
	Placebo		Low Dose		High Dose		Placebo		Low Dose		High Dose		Placebo		Low Dose		High Dose	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Application site vesicles	0	(0.0)	1	(2.0)	3	(7.5)	1	(3.0)	3	(8.8)	3	(6.8)	1	(1.2)	4	(4.8)	6	(7.1)
Application site warmth	0	(0.0)	1	(2.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)
Asthenia	1	(1.9)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)	0	(0.0)
Chest discomfort	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(2.3)	0	(0.0)	0	(0.0)	1	(1.2)
Chills	0	(0.0)	0	(0.0)	0	(0.0)	1	(3.0)	1	(2.9)	0	(0.0)	1	(1.2)	1	(1.2)	0	(0.0)
Fatigue	1	(1.9)	1	(2.0)	4	(10.0)	0	(0.0)	1	(2.9)	0	(0.0)	1	(1.2)	2	(2.4)	4	(4.8)
Feeling abnormal	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(2.3)	0	(0.0)	0	(0.0)	1	(1.2)
Malaise	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(2.9)	1	(2.3)	0	(0.0)	1	(1.2)	1	(1.2)
Oedema	0	(0.0)	1	(2.0)	0	(0.0)	0	(0.0)	1	(2.9)	0	(0.0)	0	(0.0)	2	(2.4)	0	(0.0)
Oedema peripheral	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(2.3)	0	(0.0)	0	(0.0)	1	(1.2)
Pain	0	(0.0)	1	(2.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(2.3)	0	(0.0)	1	(1.2)	1	(1.2)
Injury, poisoning and procedural complications	**0**	**(0.0)**	**2**	**(4.0)**	**1**	**(2.5)**	**0**	**(0.0)**	**0**	**(0.0)**	**0**	**(0.0)**	**0**	**(0.0)**	**2**	**(2.4)**	**1**	**(1.2)**

Excoriation	0	(0.0)	0	(0.0)	1	(2.5)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)
Fall	0	(0.0)	1	(2.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)

Participants With Drug-Related Adverse Events
Weeks 0 to 12
All Participants as Treated

	f						m						Total					
	Placebo		Low Dose		High Dose		Placebo		Low Dose		High Dose		Placebo		Low Dose		High Dose	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Skin laceration	0	(0.0)	1	(2.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)
Wound	0	(0.0)	1	(2.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)
Investigations	**2**	**(3.8)**	**2**	**(4.0)**	**1**	**(2.5)**	**2**	**(6.1)**	**0**	**(0.0)**	**0**	**(0.0)**	**4**	**(4.7)**	**2**	**(2.4)**	**1**	**(1.2)**
Blood creatine phosphokinase increased	0	(0.0)	0	(0.0)	0	(0.0)	1	(3.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)	0	(0.0)
Body temperature increased	0	(0.0)	1	(2.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)
Electrocardiogram st segment depression	1	(1.9)	1	(2.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	1	(1.2)	0	(0.0)
Electrocardiogram t wave inversion	0	(0.0)	0	(0.0)	1	(2.5)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)
Heart rate increased	0	(0.0)	0	(0.0)	0	(0.0)	1	(3.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)	0	(0.0)
Heart rate irregular	1	(1.9)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)	0	(0.0)

Participants With Drug-Related Adverse Events
Weeks 0 to 12
All Participants as Treated

	f						m						Total					
	Placebo		Low Dose		High Dose		Placebo		Low Dose		High Dose		Placebo		Low Dose		High Dose	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Metabolism and nutrition disorders	**3**	**(5.7)**	**0**	**(0.0)**	**1**	**(2.5)**	**0**	**(0.0)**	**0**	**(0.0)**	**0**	**(0.0)**	**3**	**(3.5)**	**0**	**(0.0)**	**1**	**(1.2)**
Decreased appetite	1	(1.9)	0	(0.0)	1	(2.5)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)	1	(1.2)
Food craving	1	(1.9)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)	0	(0.0)
Increased appetite	1	(1.9)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)	0	(0.0)
Musculoskeletal and connective tissue disorders	**0**	**(0.0)**	**0**	**(0.0)**	**0**	**(0.0)**	**1**	**(3.0)**	**0**	**(0.0)**	**1**	**(2.3)**	**1**	**(1.2)**	**0**	**(0.0)**	**1**	**(1.2)**
Myalgia	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(2.3)	0	(0.0)	0	(0.0)	1	(1.2)
Shoulder pain	0	(0.0)	0	(0.0)	0	(0.0)	1	(3.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)	0	(0.0)
Nervous system disorders	**3**	**(5.7)**	**8**	**(16.0)**	**7**	**(17.5)**	**2**	**(6.1)**	**4**	**(11.8)**	**8**	**(18.2)**	**5**	**(5.8)**	**12**	**(14.3)**	**15**	**(17.9)**
Balance disorder	0	(0.0)	1	(2.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)
Burning sensation	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	2	(4.5)	0	(0.0)	0	(0.0)	2	(2.4)
Complex partial seizures	0	(0.0)	1	(2.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)

Participants With Drug-Related Adverse Events
Weeks 0 to 12
All Participants as Treated

	f						m						Total					
	Placebo		Low Dose		High Dose		Placebo		Low Dose		High Dose		Placebo		Low Dose		High Dose	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Coordination abnormal	0	(0.0)	1	(2.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)
Dizziness	1	(1.9)	3	(6.0)	2	(5.0)	1	(3.0)	3	(8.8)	4	(9.1)	2	(2.3)	6	(7.1)	6	(7.1)
Headache	2	(3.8)	0	(0.0)	1	(2.5)	0	(0.0)	1	(2.9)	0	(0.0)	2	(2.3)	1	(1.2)	1	(1.2)
Hypersomnia	0	(0.0)	0	(0.0)	1	(2.5)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)
Lethargy	0	(0.0)	0	(0.0)	1	(2.5)	0	(0.0)	1	(2.9)	0	(0.0)	0	(0.0)	1	(1.2)	1	(1.2)
Paraesthesia oral	0	(0.0)	1	(2.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)
Parosmia	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(2.3)	0	(0.0)	0	(0.0)	1	(1.2)
Somnolence	0	(0.0)	0	(0.0)	0	(0.0)	1	(3.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)	0	(0.0)
Stupor	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(2.9)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)
Syncope	0	(0.0)	4	(8.0)	2	(5.0)	0	(0.0)	0	(0.0)	1	(2.3)	0	(0.0)	4	(4.8)	3	(3.6)
Syncope vasovagal	0	(0.0)	0	(0.0)	1	(2.5)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)
Transient ischaemic attack	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(2.9)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)
Psychiatric	**1**	**(1.9**	**6**	**(12.**	**1**	**(2.5**	**1**	**(3.0**	**3**	**(8.8**	**4**	**(9.1**	**2**	**(2.3**	**9**	**(10.**	**5**	**(6.0**

disorders		**)**		**0)**		**)**		**)**		**)**		**)**		**)**		**7)**		**)**
Agitation	0	(0.0)	2	(4.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	2	(2.4)	0	(0.0)

Participants With Drug-Related Adverse Events
Weeks 0 to 12
All Participants as Treated

	f						m						Total					
	Placebo		Low Dose		High Dose		Placebo		Low Dose		High Dose		Placebo		Low Dose		High Dose	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Anxiety	0	(0.0)	3	(6.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	3	(3.6)	0	(0.0)
Confusional state	0	(0.0)	1	(2.0)	0	(0.0)	1	(3.0)	1	(2.9)	0	(0.0)	1	(1.2)	2	(2.4)	0	(0.0)
Delirium	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(2.3)	0	(0.0)	0	(0.0)	1	(1.2)
Depressed mood	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(2.9)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)
Hallucination, visual	0	(0.0)	0	(0.0)	1	(2.5)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)
Insomnia	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	2	(4.5)	0	(0.0)	0	(0.0)	2	(2.4)
Irritability	1	(1.9)	1	(2.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	1	(1.2)	0	(0.0)
Libido decreased	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(2.3)	0	(0.0)	0	(0.0)	1	(1.2)
Listless	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(2.3)	0	(0.0)	0	(0.0)	1	(1.2)
Restlessness	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(2.9)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)
Renal and urinary disorders	**0**	**(0.0)**	**1**	**(2.0)**	**0**	**(0.0)**	**0**	**(0.0)**	**0**	**(0.0)**	**1**	**(2.3)**	**0**	**(0.0)**	**1**	**(1.2)**	**1**	**(1.2)**
Enuresis	0	(0.0)	1	(2.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)
Micturition	0	(0.0	0	(0.0	0	(0.0	0	(0.0	0	(0.0	1	(2.3	0	(0.0	0	(0.0	1	(1.2

urgency	)	)	)	)	)	)	)	)	)

Participants With Drug-Related Adverse Events
Weeks 0 to 12
All Participants as Treated

	f						m						Total					
	Placebo		Low Dose		High Dose		Placebo		Low Dose		High Dose		Placebo		Low Dose		High Dose	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Reproductive system and breast disorders	**1**	**(1.9)**	**0**	**(0.0)**	**0**	**(0.0)**	**0**	**(0.0)**	**0**	**(0.0)**	**0**	**(0.0)**	**1**	**(1.2)**	**0**	**(0.0)**	**0**	**(0.0)**
Pelvic pain	1	(1.9)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)	0	(0.0)
Respiratory, thoracic and mediastinal disorders	**2**	**(3.8)**	**0**	**(0.0)**	**0**	**(0.0)**	**0**	**(0.0)**	**0**	**(0.0)**	**0**	**(0.0)**	**2**	**(2.3)**	**0**	**(0.0)**	**0**	**(0.0)**
Dyspnoea	1	(1.9)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)	0	(0.0)
Emphysema	1	(1.9)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)	0	(0.0)
Skin and subcutaneous tissue disorders	**12**	**(22.6)**	**21**	**(42.0)**	**13**	**(32.5)**	**5**	**(15.2)**	**18**	**(52.9)**	**26**	**(59.1)**	**17**	**(19.8)**	**39**	**(46.4)**	**39**	**(46.4)**
Blister	0	(0.0)	2	(4.0)	0	(0.0)	0	(0.0)	3	(8.8)	1	(2.3)	0	(0.0)	5	(6.0)	1	(1.2)
Cold sweat	0	(0.0)	0	(0.0)	0	(0.0)	1	(3.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)	0	(0.0)
Dermatitis contact	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(2.9)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)
Erythema	6	(11.3)	7	(14.0)	7	(17.5)	3	(9.1)	6	(17.6)	7	(15.9)	9	(10.5)	13	(15.5)	14	(16.7)
Hyperhidrosis	1	(1.9	1	(2.0	2	(5.0	0	(0.0	3	(8.8	6	(13.	1	(1.2	4	(4.8	8	(9.5

Pruritus	6	) (11.3)	12	) (24.0)	11	) (27.5)	1	) (3.0)	9	) (26.5)	15	6) (34.1)	7	) (8.1)	21	) (25.0)	26	) (31.0)

Participants With Drug-Related Adverse Events
Weeks 0 to 12
All Participants as Treated

	f						m						Total					
	Placebo		Low Dose		High Dose		Placebo		Low Dose		High Dose		Placebo		Low Dose		High Dose	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Pruritus generalised	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(2.9)	1	(2.3)	0	(0.0)	1	(1.2)	1	(1.2)
Rash	2	(3.8)	6	(12.0)	2	(5.0)	1	(3.0)	5	(14.7)	5	(11.4)	3	(3.5)	11	(13.1)	7	(8.3)
Rash erythematous	0	(0.0)	1	(2.0)	0	(0.0)	0	(0.0)	1	(2.9)	0	(0.0)	0	(0.0)	2	(2.4)	0	(0.0)
Rash maculo-papular	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(2.3)	0	(0.0)	0	(0.0)	1	(1.2)
Rash papular	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(2.3)	0	(0.0)	0	(0.0)	1	(1.2)
Rash pruritic	0	(0.0)	1	(2.0)	1	(2.5)	0	(0.0)	0	(0.0)	1	(2.3)	0	(0.0)	1	(1.2)	2	(2.4)
Skin exfoliation	0	(0.0)	1	(2.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)
Skin irritation	2	(3.8)	5	(10.0)	1	(2.5)	0	(0.0)	1	(2.9)	4	(9.1)	2	(2.3)	6	(7.1)	5	(6.0)
Skin ulcer	0	(0.0)	0	(0.0)	0	(0.0)	1	(3.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)	0	(0.0)
Urticaria	0	(0.0)	0	(0.0)	1	(2.5)	0	(0.0)	1	(2.9)	0	(0.0)	0	(0.0)	1	(1.2)	1	(1.2)
Vascular disorders	**0**	**(0.0)**	**2**	**(4.0)**	**1**	**(2.5)**	**1**	**(3.0)**	**0**	**(0.0)**	**0**	**(0.0)**	**1**	**(1.2)**	**2**	**(2.4)**	**1**	**(1.2)**
Hypertension	0	(0.0)	1	(2.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)
Hypotension	0	(0.0	1	(2.0	0	(0.0	1	(3.0	0	(0.0	0	(0.0	1	(1.2	1	(1.2	0	(0.0

Orthostatic hypotension	0	) (0.0)	0	) (0.0)	0	) (0.0)	1	) (3.0)	0	) (0.0)	0	) (0.0)	1	) (1.2)	0	) (0.0)	0	) (0.0)

Participants With Drug-Related Adverse Events
Weeks 0 to 12
All Participants as Treated

	f						m						Total					
	Placebo		Low Dose		High Dose		Placebo		Low Dose		High Dose		Placebo		Low Dose		High Dose	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Wound haemorrhage	0	(0.0)	0	(0.0)	1	(2.5)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)

Every participant is counted a single time for each applicable row and column.
A system organ class or specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.
Adverse event terms are from MedDRA Version 24.0.

Source: [CDISCpilot: adam-adsl; adae]